Skip to main content
main-content

01.12.2012 | Case report | Ausgabe 1/2012 Open Access

World Journal of Surgical Oncology 1/2012

Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields

Zeitschrift:
World Journal of Surgical Oncology > Ausgabe 1/2012
Autoren:
Aaron Michael Rulseh, Jiří Keller, Jan Klener, Jan Šroubek, Vladimír Dbalý, Martin Syrůček, František Tovaryš, Josef Vymazal
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1477-7819-10-220) contains supplementary material, which is available to authorized users.

Competing interests

JV, JS, VD and FT are consultants for NovoCure, Ltd, Haifa, Israel. AMR, JiK, JaK and MS have no competing interests to declare.

Authors’ contributions

JV participated in conception and design of the manuscript; acquisition, analysis and interpretation of the data; initial drafting and revision of the manuscript; and approval of the final version. AMR participated in conception and design of the manuscript, drafting and revision of the manuscript, preparation of images and approval of the final version. JiK participated in conception and design of the manuscript, drafting and revision of the manuscript and approval of final version. JaK, JS, VD, MS and FT participated in the acquisition, analysis and interpretation of the data, revision of the manuscript and approval of the final version. All authors read and approved the final manuscript.

Abstract

Glioblastoma multiforme (GBM) is the most common and malignant primary intracranial tumor, and has a median survival of only 10 to 14 months with only 3 to 5% of patients surviving more than three years. Recurrence (RGBM) is nearly universal, and further decreases the median survival to only five to seven months with optimal therapy. Tumor-treating fields (TTField) therapy is a novel treatment technique that has recently received CE and FDA approval for the treatment of RGBM, and is based on the principle that low intensity, intermediate frequency electric fields (100 to 300 kHz) may induce apoptosis in specific cell types. Our center was the first to apply TTField treatment to histologically proven GBM in a small pilot study of 20 individuals in 2004 and 2005, and four of those original 20 patients are still alive today. We report two cases of GBM and two cases of RGBM treated by TTField therapy, all in good health and no longer receiving any treatment more than seven years after initiating TTField therapy, with no clinical or radiological evidence of recurrence.
Zusatzmaterial
Authors’ original file for figure 1
12957_2012_1142_MOESM1_ESM.tiff
Authors’ original file for figure 2
12957_2012_1142_MOESM2_ESM.tiff
Authors’ original file for figure 3
12957_2012_1142_MOESM3_ESM.tiff
Authors’ original file for figure 4
12957_2012_1142_MOESM4_ESM.tiff
Authors’ original file for figure 5
12957_2012_1142_MOESM5_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

World Journal of Surgical Oncology 1/2012 Zur Ausgabe

Neu im Fachgebiet Chirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise